Resumo

ZENZOLA, Víctor  et al. Cirugía citorreductora posterior a quimioterapia neoadyuvante: en cáncer epitelial de ovario avanzado. Rev. venez. oncol. [online]. 2005, vol.17, n.3, pp.122-128. ISSN 0798-0582.

SUMMARY OBJECTIVE: To determine the feasibility of optimal cytoreduction after neoadjuvant chemotherapy in epithelia advanced ovarian cancer and relation it with the global survival and disease free survival. METHOD: 22 patients with advanced epithelial cancer of ovary selected according Vergote´s indications: bulky disease, multiply implants, and parenchyma disease metastasis, it administrated 3 or 4 cycles of chemotherapy with carboplatinumtaxans and after interval surgery. The statistical analysis was based on porcentual relations, variable analysis and Pearson variable correlation test. RESULTS: All the patients were catalogued as stage III-C or IV by FIGO classification. Adenocarcinoma without specification was the most important histological subtype with the (45.5 %). 63.6 % were poor differentiation tumors. All the patients responded to neoadyuvant chemotherapy, even there was a complete pathological response in five. Optimal cytoreduction surgery was achieved in 81.8 % of the patients. The median in follow up was 18 months, 20 patients are lived (90.9 %) and 14 without disease. In 4 patients had persistence of the disease, 2 of them died because of these, in 4 patients recurrent disease was described, Disease free survival registers a media of 11.45 months. The unique factor relationated with disease free survival was the capacity to realize optimal cytoreductive surgery (P= 0.006). CONCLUSIONS: The primary cytoreductive surgery is still the gold standard in treatment of advanced epithelian ovarian carcinoma, neoadjuvant chemotherapy and interval debulky surgery is a valid option in a subgroup of patients with adverse prognostic factors.

Palavras-chave : Cancer; ovarian; treatment; interval surgery; chemotherapy.